

## Contents

**Preface** XV

**Introduction** XVII

**Abbreviations** XXI

### **Part I**    **General Aspects**    1

#### **1**    **Optimizing Drug Therapy by Analogues**    3

*János Fischer, C. Robin Ganellin, John Proudfoot, and Erika M. Alapi*

1.1    Introduction    3

1.2    Pharmacodynamic Characteristics    4

1.2.1    Potency    4

1.2.2    Improving the Ratio of Main Activity and Adverse Effects    5

1.2.2.1    Improving Selectivity Through Receptor Subtypes    6

1.2.2.2    Improving Selectivity Through Unrelated Receptors    7

1.2.2.3    Improving Selectivity by Tissue Distribution    7

1.2.2.4    Improving Selectivity of Nonreceptor-Mediated Effects    10

1.2.3    Improving the Physicochemical Properties with Analogues    10

1.2.4    Analogues to Reduce the Resistance to Anti-Infective Drugs    11

1.2.4.1    Antibiotics    11

1.2.4.2    Antifungal Drugs    12

1.2.4.3    Antiviral Drugs    12

1.2.5    Analogue Research in Resistance to Drug Therapies in Cancer Treatment    15

1.3    Pharmacokinetic Characteristics    15

1.3.1    Improving Oral Bioavailability    15

1.3.1.1    Improving Absorption    16

1.3.1.2    Improving Metabolic Stability    16

1.3.2    Drugs with a Long Duration of Action    17

1.3.3    Ultrashort-Acting Drugs    18

1.3.4    Decreasing Interindividual Pharmacokinetic Differences    20

1.3.5    Decreasing Systemic Activity    21

1.4	Drug Interactions	22
1.4.1	Decreasing Drug Interactions	22
1.4.2	Increasing Drug Interactions	23
1.5	Summary	23
	References	24
<b>2</b>	<b>Standalone Drugs</b>	<b>29</b>
	<i>János Fischer, C. Robin Ganellin, Arun Ganesan, and John Proudfoot</i>	
2.1	Acetaminophen (Paracetamol)	30
2.2	Acetylsalicylic Acid (Aspirin)	33
2.3	Aripiprazole	35
2.3.1	First Generation “Typical” Antipsychotic Drugs (Other Names: Neuroleptics, Conventional Antipsychotics)	36
2.3.2	Second-Generation “Atypical” Antipsychotic Drugs	37
2.3.3	A New Approach: Aripiprazole, a Dopamine Partial Agonist	38
2.4	Bupropion	39
2.5	Ezetimibe	42
2.6	Lamotrigine	46
2.7	Metformin	47
2.8	Topiramate	49
2.9	Valproate	51
2.10	Summary	52
	References	53
<b>3</b>	<b>Application of Molecular Modeling in Analogue-Based Drug Discovery</b>	<b>61</b>
	<i>György G. Ferenczy</i>	
3.1	Introduction	61
3.2	Cilazapril: An ACE Inhibitor	62
3.3	Atorvastatin: A HMG-CoA Reductase Inhibitor	66
3.4	PDE4 Inhibitors	70
3.5	GPIIb/IIIa Antagonists	73
3.6	HIV Protease Inhibitors	74
3.7	Epilogue	79
	References	79
<b>4</b>	<b>Issues for the Patenting of Analogues</b>	<b>83</b>
	<i>Stephen C. Smith</i>	
4.1	Introduction	83
4.2	Patents: Some Fundamentals	84
4.3	Patentability	85
4.4	Important Elements of the International Patent System	86
4.5	Priority	87
4.6	Novelty	88
4.7	Inventive Step: Nonobviousness	90

4.8	Utility: Industrial Application	93
4.9	Selection Inventions	93
4.10	Enantiomers	94
4.11	Prodrugs and Active Metabolites	95
4.12	The Patenting Process from the Inventor's Standpoint	97
4.12.1	Inventorship	98
4.12.2	The Priority Patent Application	98
4.12.3	Prior Art Disclosure	98
4.12.4	Patent Specification Review	99
4.12.5	"Best Mode" of Carrying Out the Invention	99
4.12.6	Foreign Patent Applications	99
4.12.7	Patent Application Publication	100
4.12.8	Patent Examination	100
4.12.9	Opposition to Grant	101
4.12.10	Patent Litigation	102
4.13	Pitfalls for the Unwary: Granted Versus Published Patents, Scientific Publications	102
	References	105

## Part II Analogue Classes 107

### 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes 109

*Jens-Uwe Peters and Patrizio Mattei*

5.1	Introduction	109
5.2	<i>In Vitro</i> Assays and Animal Models for the Assessment of DPP-IV Inhibitors	110
5.3	Substrate-Based DPP-IV Inhibitors	110
5.4	Sitagliptin and Analogues	119
5.5	Xanthines and Analogues	122
5.6	Pharmacological Comparison of DPP-IV Inhibitors	125
5.7	Concluding Remarks	127
	References	128

### 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction 135

*Nils Griebenow, Helmut Haning, and Erwin Bischoff*

6.1	Introduction	135
6.2	Pharmacology of Phosphodiesterases	136
6.2.1	The Phosphodiesterase Family	136
6.2.2	Pharmacological Effects of cGMP	137
6.2.3	PDE5: Regulation, Activation, and Structure	138
6.2.4	PDE5 Inhibitors and Erectile Dysfunction	143
6.3	Pyrimidinone PDE5 Inhibitors	147
6.3.1	Xanthines and cGMP Analogues	147
6.3.2	PDE5 Inhibitors Incorporating the Purinone Nucleus	150

6.3.2.1	Zaprinast	150
6.3.2.2	Purinones	150
6.3.3	Pyrazolopyrimidinone PDE5 Inhibitors	151
6.3.3.1	Pyrazolo[3,4-d]Pyrimidin-4-One PDE5 Inhibitors	151
6.3.3.2	1,6-Dihydro-7H-Pyrazolo[4,3-d]Pyrimidin-4-One PDE5 Inhibitors	152
6.3.4	Imidazotriazinone PDE5 Inhibitors	154
6.3.5	Imidazoquinazolinones	155
6.3.6	Pyrazolopyridopyrimidines	156
6.3.7	Miscellaneous Heterocyclic-Fused Pyrimidinone PDE5 Inhibitors	156
6.4	Nonpyrimidone PDE5 Inhibitors	160
6.4.1	Hexahydropyrazino-Pyrido-Indole-1,4-Diones	160
6.5	Conclusions	162
	References	162
<b>7</b>	<b>Rifamycins, Antibacterial Antibiotics and Their New Applications</b>	<b>173</b>
	<i>Enrico Selva and Giancarlo Lancini</i>	
7.1	Discovery of the Pioneer Drug	173
7.2	Clinically Used Rifamycins	173
7.3	Mode of Action of Rifamycins and Structural Requirements for Activity	174
7.4	Modulation of Chemotherapeutic Properties	177
7.5	Profiles of Rifamycins Targeted at Tuberculosis Treatment	177
7.6	Rifampicin (INN), Rifampin (USAN)	178
7.7	Rifapentine	180
7.8	Rifabutin	181
7.9	Rifamycins Beyond Tuberculosis	181
7.10	Rifamycin SV and Rifamide	182
7.11	Rifaximin	182
7.12	Trials for Other Therapeutic Indications	183
7.13	Summary	183
	References	184
<b>8</b>	<b>Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs</b>	<b>189</b>
	<i>Andr�s Nemes</i>	
8.1	Introduction	189
8.2	Vincamine and Derivatives: Cerebrovascular and Neuroprotective Agents	190
8.2.1	Medicinal Chemistry of Vincamine Derivatives	190
8.2.1.1	Structure–Activity Relationships	192
8.2.2	Synthesis of Vincamine Derivatives	193
8.2.3	Pharmacological Properties of Vincamine Derivatives	193
8.2.3.1	Mechanism of Action	193
8.2.3.2	Clinical Pharmacology	194
8.3	Antitumor Dimeric Vinca Alkaloids	195
8.3.1	Medicinal Chemistry of Dimeric Vinca Alkaloid Derivatives	195

8.3.1.1	Structure–Activity Relationships	196
8.3.2	Synthesis of Dimeric Vinca Alkaloid Derivatives	198
8.3.3	Pharmacological Properties of Dimeric Vinca Alkaloid Derivatives	199
8.3.3.1	Mechanism of Action	199
8.3.3.2	Clinical Pharmacology	199
8.4	Antitumor Camptothecin Derivatives	201
8.4.1	Medicinal Chemistry of Camptothecin Derivatives	201
8.4.1.1	Structure–Activity Relationships	202
8.4.2	Synthesis of Camptothecin Derivatives	203
8.4.3	Pharmacological Properties of Camptothecin Derivatives	204
8.4.3.1	Mechanism of Action	204
8.4.3.2	Clinical Pharmacology	205
8.5	Summary and Conclusions	207
	References	207
<b>9</b>	<b>Anthracyclines, Optimizing Anticancer Analogues</b>	<b>217</b>
	<i>Federico-Maria Arcamone</i>	
9.1	Introduction: Biosynthetic Antitumor Anthracyclines	217
9.2	Analogues with Modification of the Aminosugar Moiety	219
9.3	Analogues with Modifications in the Anthraquinone Moiety	223
9.4	Analogues Modified on Ring A of the Aglycone	226
9.5	Disaccharide Analogues	229
9.6	Other Compounds	232
9.7	Summary and Final Remarks	233
	References	234
<b>10</b>	<b>Paclitaxel and Etoposide Analogues, Anticancer Drugs</b>	<b>243</b>
	<i>Paul W. Erhardt and Mohammad El-Dakdouki</i>	
10.1	Introduction	243
10.2	Discovery and Development of Paclitaxel	243
10.3	Clinical Success and Shortcomings of Paclitaxel	245
10.4	ABDD Leading to Docetaxel	247
10.5	Additional Structural Analogues	249
10.6	The Pursuit of Microtubule-Stabilizing Pharmacological Analogues	250
10.7	The Etoposides	252
10.8	ABDD and Development Leading to Ixabepilone	258
10.9	Conclusions	260
	References	263
<b>11</b>	<b>Selective Serotonin Reuptake Inhibitors for the Treatment of Depression</b>	<b>269</b>
	<i>Wayne E. Childers Jr. and David P. Rotella</i>	
11.1	Introduction	269
11.2	Neurochemistry and Mechanism of Action	270

- 11.3 Preclinical Pharmacology 271
  - 11.3.1 Sertraline 271
  - 11.3.2 Escitalopram 272
  - 11.3.3 Fluvoxamine 273
  - 11.3.4 Fluoxetine 274
  - 11.3.5 Paroxetine 275
- 11.4 Medicinal Chemistry 276
  - 11.4.1 Sertraline 276
  - 11.4.2 Escitalopram 278
  - 11.4.3 Fluvoxamine 279
  - 11.4.4 Fluoxetine 281
  - 11.4.5 Paroxetine 284
- 11.5 Comparison of SSRIs and Other Uses 285
- 11.6 Summary 288
  - References 288
  
- 12 Muscarinic Receptor Antagonists in the Treatment of COPD 297**  
*Matthias Grauert, Michael P. Pieper, and Paola Casarosa*
  - 12.1 Introduction 297
  - 12.2 Muscarinic Receptor Subtypes 298
  - 12.3 Structures of Muscarinic Agonists and Antagonists 299
    - 12.3.1 Muscarinic Agonists 299
    - 12.3.2 Antimuscarinics 300
    - 12.3.3 Discovery of Quaternary Antimuscarinics 303
    - 12.3.4 Once-Daily Quaternary Antimuscarinics: Tiotropium Bromide as the Gold Standard 305
  - 12.4 Preclinical Pharmacology. Comparison of Ipratropium and Tiotropium 309
    - 12.4.1 Bronchoconstriction in Conscious Guinea Pigs According to the Method of Kallos and Pagel 310
    - 12.4.2 Bronchoconstriction in Anaesthetized Dogs 310
  - 12.5 Clinical Pharmacology 311
  - 12.6 Antimuscarinics in Clinical Development for the Treatment of COPD 313
  - 12.7 Summary 313
    - References 314
  
- 13  $\beta$ -Adrenoceptor Agonists and Asthma 319**  
*Giovanni Gaviraghi*
  - 13.1 Introduction 319
  - 13.2 First-Generation  $\beta_2$ -Agonists: The Short-Acting Bronchodilators 319
  - 13.3 Second-Generation  $\beta_2$ -Agonists: Further Derivatives of Salbutamol 321
  - 13.4 Third-Generation  $\beta_2$ -Agonists: The Long-Acting Bronchodilators 321

13.5	Combination Therapy with LABA and Corticosteroids	326
13.6	Future Directions: Once-a-Day Therapy and Bifunctional Muscarinic Antagonist- $\beta_2$ -Agonist (MABA)	327
	References	329
<b>Part III</b>	<b>Case Histories</b>	<b>333</b>
<b>14</b>	<b>Liraglutide, a GLP-1 Analogue to Treat Diabetes</b>	<b>335</b>
	<i>Lotte B. Knudsen</i>	
14.1	Introduction	335
14.2	Discussion	338
14.2.1	Physiology of Native GLP-1	338
14.2.2	Development of Liraglutide: A GLP-1 Analogue	339
14.2.3	The Pharmacology of Liraglutide	346
14.2.4	Clinical Evidence with Liraglutide	349
14.3	Summary	350
	References	351
<b>15</b>	<b>Eplerenone: Selective Aldosterone Antagonist</b>	<b>359</b>
	<i>Jaroslav Kalvoda and Marc de Gasparo</i>	
15.1	Introduction	359
15.2	Development of a Specific and Selective Aldosterone Antagonist	360
15.3	Eplerenone: Selectivity and Specificity	367
15.4	Preclinical Development of Eplerenone: From Animal to Man	373
15.5	Further Development of Eplerenone	375
15.6	Conclusions	376
15.7	Epilogue	376
	References	377
<b>16</b>	<b>Clevudine, to Treat Hepatitis B Viral Infection</b>	<b>383</b>
	<i>Ashoke Sharon, Ashok K. Jha, and Chung K. Chu</i>	
16.1	Current Status of Anti-HBV Agents	383
16.1.1	Nucleoside Reverse Transcriptase Inhibitors	386
16.2	Chemical Evolution of Clevudine	387
16.2.1	Development of Synthetic Routes	387
16.2.2	Structure-Activity Relationships	388
16.3	Metabolism and Mechanism of Action	390
16.4	Pharmacokinetics	392
16.4.1	Woodchuck Studies	393
16.5	Clinical Studies	394
16.6	Drug Resistance	396
16.7	Toxicity and Tolerability	398
16.8	Dosage and Administration	399
16.9	Combination Therapy	399
16.9.1	Combination of Clevudine with Other Agents	399

16.9.2	Combination of Clevudine with Vaccine	400
16.10	Summary	400
	References	401
<b>17</b>	<b>Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1</b>	<b>409</b>
	<i>Jerome Guillemont, Luc Geeraert, Jan Heeres, and Paul J. Lewi</i>	
17.1	Introduction	409
17.2	Chemistry	412
17.2.1	Synthesis of TMC278 and Close Analogues	412
17.2.2	Modulation of the Central Heterocycle Core	418
17.2.3	C-5 Substitution of the Pyrimidine Core	419
17.3	Structure–Activity Relationships	420
17.3.1	Introduction of G Spacer Between the Aryl Ring and the Cyano Group	421
17.3.2	Modulation of Substituents at C-2 and C-6 on the Left Wing and of the Linker Between Left Wing and Pyrimidine Core	423
17.3.3	Substitution at C-5 Position of the Pyrimidine Heterocycle	424
17.3.4	Modification of the Central Heterocycle Core	426
17.4	TMC278: Physicochemical Properties	429
17.5	Modeling of TMC278 and Crystal Structure	430
17.6	Pharmacokinetic and Phase II Studies of TMC278	431
17.7	Conclusions	434
	References	434
<b>18</b>	<b>Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV</b>	<b>443</b>
	<i>Suvit Thaisrivongs, Joseph W. Strohbach, and Steve R. Turner</i>	
18.1	Human Immunodeficiency Virus	443
18.2	HIV Protease	443
18.2.1	HIV PIs	444
18.3	Approaches to Identifying and Developing PI Leads	446
18.3.1	Focused Screening	446
18.3.2	Broad Screening for Nonpeptidic Leads	447
18.3.3	Structure-Based Drug Design	448
18.3.3.1	PNU-96988, A First-Generation Clinical Candidate	449
18.3.3.2	PNU-103017, A Second-Generation Clinical Candidate	450
18.3.3.3	Tipranavir, The Third Generation	453
18.4	Characteristics of Tipranavir	454
18.4.1	<i>In Vitro</i> Activity	454
18.4.2	Pharmacokinetics	455
18.4.3	Highlights of Clinical Data	456
18.5	Fragment-Based Lead Development?	457
18.6	Summary	458
	References	459

<b>19</b>	<b>Lapatinib, an Anticancer Kinase Inhibitor</b>	<b>465</b>
	<i>Karen Lackey</i>	
19.1	Introduction	465
19.2	Aims	467
19.3	Chemical Evolution and Proof-of-Mechanistic Approach Using Small Molecules	469
19.4	Final Set of Analogues that Led to the Discovery of Lapatinib	474
19.4.1	6-Furanyl Quinazoline Series	474
19.4.2	6-Thiazolylquinazoline Series	479
19.4.3	Alkynylpyrimidine Series	480
19.5	Final Selection Criteria and Data	482
19.6	Early Clinical Results	487
19.7	Prospects for Kinase Inhibitors	489
	References	490
<b>20</b>	<b>Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia</b>	<b>493</b>
	<i>Jagabandhu Das and Joel C. Barrish</i>	<b>493</b>
20.1	Introduction	493
20.2	Discussion	494
20.3	Clinical Findings and Summary	502
	References	503
<b>21</b>	<b>Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder</b>	<b>507</b>
	<i>Magid Abou-Gharbia and Wayne E. Childers Jr.</i>	
21.1	Introduction	507
21.2	Major Depressive Disorder	510
21.3	MDD Pharmacotherapy	511
21.4	The Discovery of Venlafaxine	511
21.4.1	Identification of an Early Lead (WY-44362)	511
21.4.2	Structure–Activity Relationship Studies	512
21.4.3	<i>In Vivo</i> Animal Models of Preclinical Efficacy	514
21.4.4	Selection of WY-45030 for Clinical Trials	514
21.5	Clinical Efficacy of Effexor <sup>®</sup>	515
21.6	An Extended Release Formulation – Effexor XR <sup>®</sup>	516
21.7	Discovery of a Second-Generation SNRI – O-Desmethylvenlafaxine	516
21.8	Effexor and Pristiq – Additional Considerations	518
21.8.1	Effexor	518
21.8.1.1	Onset of Action	518
21.8.1.2	Treatment of Some Anxiety Disorders	519
21.8.1.3	Painful Somatic Symptoms	519
21.8.2	Pristiq	519

**XIV** | *Contents*

21.8.2.1	Anxiety and Painful Symptoms	519
21.8.2.2	Symptoms Associated with Menopause	519
21.9	Conclusions	520
	References	520

<b>Index</b>	525
--------------	-----